Introduction
Stroke is a leading cause of death and disability in adults, 1 and pregnancy is the first increased stroke risk period for women.
2, 3 While its occurrence as a complication of pregnancy is relatively rare, the impact on the mother, child, and families can be devastating. A recent estimate suggests that stroke affects 30/100,000 pregnancies, 4 roughly three times higher than that seen in the general population of young adults. 5 Stroke during pregnancy most often occurs close to the time of delivery (40%) and in the postpartum period (50%). 4 Several aspects of pregnancy can increase the risk of stroke including hypertensive disorders of pregnancy 6 and their complications, HELLP syndrome (hemolysis, elevated liver enzymes and low platelets syndrome), hematologic and prothrombotic changes in the third trimester and postpartum periods, hyperemesis resulting in hemoconcentration, and changes to cerebral vasculature.
When a stroke occurs in pregnancy, a predetermined approach to coordinated care is essential to achieve the best possible outcome. Typical decisions made when managing the non-pregnant patient must be modified to accommodate additional issues such as the timing of stroke within the pregnancy, stroke severity, expected maternal outcomes, and the known or theoretical impact of decisions and interventions on the fetus. Whenever possible, the same decision-making process used for acute treatment and management outside of pregnancy should be considered for a woman who is pregnant. In these cases, maternal health is prioritized and delays or deferral of critical steps in diagnosis and life-saving care due to pregnancy should be minimized.
This consensus statement document was developed in recognition of the need for a systematic, rational approach to management decisions given the lack of other guidelines or consensus statements currently available that address this group. While stroke during pregnancy is relatively rare, it is sufficiently common that most specialists providing either obstetrical or stroke care encounter women with a past stroke wanting to get pregnant, or women who develop a stroke during or just after a pregnancy. This consensus statement document is focused on issues associated with acute stroke assessment and management for a woman who experiences an acute stroke during pregnancy or in the early postpartum period and was developed through an interdisciplinary collaborative effort between stroke and maternal-fetal medicine experts. Issues addressed in this document include initial emergency management, diagnostic imaging, acute stroke treatment, the management of hemorrhagic stroke, anesthetic management, post stroke management for women with a stroke in pregnancy, intrapartum considerations, and postpartum management. The evidence used to inform the consensus statement is derived primarily from studies of either general stroke or general pregnancy cohorts. Since pregnancy has been an exclusion criterion from virtually all acute stroke trials, and due to the relative rarity of stroke events in this group, there is a lack of high-quality evidence from randomized controlled trials from which to draw upon. Consequently, we have also used data obtained from case reports, case series, and population-based registries to inform the development of the consensus statements. These statements also reflect expert opinion, which is based on professional and clinical experience. While these statements are not intended to replace the role of integrated, interdisciplinary discussions related to specific cases or supersede clinician judgment and patient preferences, they may help to guide time-sensitive decisions that can reduce morbidity and mortality.
This consensus statement is the second of a two-part Canadian Stroke Best Practice Recommendations (CSBPR) Stroke in Pregnancy series developed for use by healthcare professionals across all disciplines that provide care to women planning a pregnancy who have a prior history of stroke or transient ischemic attack, or women who sustain a stroke during pregnancy. The first part 7 focuses on the unique aspects of secondary stroke prevention in a woman with a prior history of stroke who is, or is planning to become, pregnant and addresses counseling, monitoring, and the safety of select pharmacotherapy on maternal and fetal health while minimizing risks of a recurrent stroke. The second part focuses on the acute management of a woman who experiences a stroke while pregnant.
Conceptual framework
Underlying these recommendations are several important concepts that guide the approach to complex and potentially high-risk scenarios involving pregnant women. 8 First is the concept that maternal health is vital for fetal well-being. All decisions ultimately need consideration of the risks and benefits for both mother and fetus, but maternal health should be a prime consideration. Second, management decisions should be based on the nexus of two clinical considerations: (a) what decisions would be made if the patient wasn't pregnant? and (b) what decisions would be made if the patient hadn't had a stroke? Existing guidelines and recommendations for standard of care treatments for both stroke and for pregnancy should be considered first and tailored as necessary to accommodate individual patient circumstances. [9] [10] [11] [12] Third, where possible, an interdisciplinary team approach is needed to address the complex care and management decisions and should involve those with stroke and obstetrical expertise, in addition to the patient and family. Finally, decisions must be individualized based on the specific situation. A given management decision may be influenced by many factors. Some key factors include the timing since stroke onset, severity of the stroke and residual deficits, bleeding risk associated with the stroke, pregnancy or delivery, etiology of the stroke and future stroke risk, timing within pregnancy, maternal age, medical comorbidities, obstetrical history, access to subspecialty services, and the goals and preferences of the individual woman and their family.
The CSBPR for the Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care was updated in parallel with the development of this consensus statement and appears in this issue of the journal (see www.strokebestpractices.ca). These stroke recommendations, applicable for all individuals who have experienced a stroke, should be reviewed in conjunction with this statement, as should recommendations for management of pregnancy from the Society of Obstetricians and Gynecologists of Canada, available at https://sogc. org/clinical_practice_guidelines_eng/index.html.
Consensus statement development methodology
This is a medical consensus statement based on the existing literature and expert opinion; it is not intended to be an evidence-based guideline, given the relative paucity of evidence directly specific to both stroke and pregnancy. Wherever possible, we have drawn on the respective stroke and pregnancy literatures. Unless otherwise explicitly stated, the statements reflect agreement within our interdisciplinary panel of experts where research evidence is weak or not available.
The Canadian Stroke in Pregnancy Consensus Statements were developed by following the same rigorous process applied to the CSBPR. 13 The methodology for developing the consensus statements included several distinct steps to ensure a thorough and systematic process. The detailed methodology and explanations for each of these steps in the development and dissemination of the CSBPR and consensus statements is available in the Canadian Stroke Best Practice Recommendations Overview and Methodology manual available on the Canadian stroke best practices website at: www.strokebestpractices.ca An interdisciplinary group of experts from stroke, maternal-fetal medicine, obstetrics, gynecology, and obstetrical anesthesia disciplines was convened to review all available evidence, discuss a range of scenarios and current reasonable practices, then drafted and edited all consensus statements. Members with extensive experience across a range of relevant clinical areas who are considered leaders and experts in their field were selected to participate. Persons with experience in the review and appraisal of research evidence and individuals (or family members of individuals) who had experienced a stroke during or prior to pregnancy were also included either as group members or external reviewers in the development process.
A comprehensive systematic literature search was conducted to identify research evidence on the management of acute stroke during pregnancy. Due to limited randomized controlled clinical trial data directly applicable to this population, trials from stroke in general and from other obstetrical literature, as well as casecontrol and observational studies were considered. The literature for this module was updated to March 2018. The writing group extensively reviewed and discussed the available evidence. Consensus was reached on all statements through a multi-round review and Modified Delphi voting process where 80% agreement was required to include a statement. Unlike our evidencebased CSBPR guidelines, evidence levels were not assigned to each consensus statement. Most statements are based on the expert opinion of International Journal of Stroke, 13 (7) the writing group. In some cases, where stronger evidence does exist, the wording of the statement is stronger (e.g. use of ''should'') to indicate confidence in the evidence.
Acute stroke management during pregnancy consensus statements
The following sections provide detailed consensus statements associated with acute stroke management during pregnancy. Issues addressed in this consensus statement document include initial emergency management, diagnostic imaging, acute stroke treatment, the management of hemorrhagic stroke, anesthetic management, poststroke management issues while the woman is still pregnant, intrapartum considerations, and postpartum management.
Initial emergency management
While stroke during pregnancy presents several additional challenges, initial emergency investigations and treatment of stroke during pregnancy, or within the six weeks thereafter, are similar to treatment in the nonpregnancy state. Rapid presentation to a stroke center for timely assessment and management represents the best opportunity for a good outcome for both mother and baby. Key issues that need to be addressed immediately include prompt neuroimaging to confirm the diagnosis and to differentiate between ischemic and hemorrhagic and the treatment of hypertension. Delay or deferral of critical steps in the diagnosis of stroke and the provision of life-saving care due to pregnancy are not warranted. In such cases, maternal health is essential for fetal well-being.
i. Where possible, rapid access to a stroke center should be sought for all pregnant women with suspected acute stroke.
Guidelines for acute stroke management outside the context of pregnancy can be found at www.strokebestpractices.ca, and these guidelines should be followed except when necessary to modify and/or individualize for maternal considerations and fetal safety. a. Acute stroke management decisions should be based on stroke type, severity of symptoms, medical condition of the patient, and, when available, consideration of the personal values and wishes of the patient and family members or next-of-kin. b. Institutions with both obstetrical and stroke specialization should have protocols in place for rapid assessment and access to appropriate pregnancy and stroke-related diagnostic tests and interventions. c. Management of acute stroke in pregnant women should reflect collaboration between stroke teams and obstetrics teams.
Rapid involvement of both teams is important to ensure the best possible outcomes for the pregnant woman and the fetus. d. Institutions that lack either obstetrical care or neurologic specialists should predefine pathways and protocols for emergent collaborative management in person or through telemedicine modalities and consider transfer to a center with appropriate neurological and obstetrical expertise, if needed. e. Education and coordination of care between the emergency department, obstetrics, stroke, and radiology services should be in place to ensure a stroke during pregnancy is considered an emergency and to facilitate access to rapid intervention. The risks of delayed stroke care should be understood at all institutions caring for pregnant women. As well arrangements should be in place to ensure an acknowledgment of the urgency in the management of severe preeclampsia with neurologic features. f. Protocols and educational efforts should be in place to help practitioners collaborate and manage pregnant or peripartum patients with either neurologic signs and symptoms and/or in the setting of possible severe preeclampsia.
ii. Protocols for rapid brain and vascular imaging will help identify an acute stroke and inform stroke etiology which may guide management (e.g. stroke secondary to preeclampsia vs. due to an arterial occlusion vs. other causes). a. Focal neurologic deficits are usually not part of preeclampsia and represent an emergency mandating interdisciplinary care. Since stroke can be secondary to preeclampsia, the presence of focal neurological deficits should alert obstetrical practitioners to the possibility of acute stroke. b. Protocols should be in place to acutely manage severe hypertension (i.e. sBP 160 mmHg or dBP 110 mmHg). In the setting of preeclampsia or severe hypertension with neurological symptoms, the goal is to achieve an urgent and sustained reduction of systolic and diastolic blood pressure to less than 160/110 mmHg to reduce the risk of maternal stroke. 10, 14, 15 c. The impact of blood pressure reduction on placental perfusion should be considered. Obstetrics/Maternal Fetal Medicine practitioners should be involved in ongoing assessments of the maternal-placental-fetal unit and decision-making related to blood pressure lowering and the approach to fetal monitoring and surveillance where appropriate. Care must be taken to not cause hypotension or hypoperfusion. 14, 16 d. Protocols for magnesium sulfate administration in cases of severe preeclampsia, to reduce the risk of eclampsia, should be in place to help standardize and facilitate rapid care in these cases.
Diagnostic imaging
Concerns about the fetal risk associated with neuroimaging and ionizing radiation are often expressed by both pregnant women and their care providers. But, given the severe maternal risk caused by potential delay in diagnosis of stroke and the small risk to the fetus of computed tomography (CT), neuroimaging with CT scanning without first confirming a pregnancy is acceptable. There is a lack of evidence on, but no known harm from, CT contrast. Magnetic resonance imaging (MRI) of the brain, even in first trimester, is not associated with increased fetal risks. 18 The use of gadolinium contrast should be avoided as gadolinium contrast exposure at any time during pregnancy has been associated with an increased risk of a broad set of rheumatological, inflammatory, or infiltrative skin conditions and with stillbirth or neonatal death. 18 When diagnostic imaging is required during the postpartum period, less than 1% of CT contrast dye is excreted into breastmilk, and the dose of iodinated contrast agent in the breastmilk absorbed by infants is 0.5% of the maternal dose; 19, 20 therefore, the continuation of breastfeeding after exposure to CT contrast does not pose any known risk to the infant. iii. New severe headaches in pregnancy may represent preeclampsia, a complication of delivery (e.g. post-LP headaches), or a more benign primary headache syndrome (e.g. migraine). However, vascular events have increased frequency in pregnancy and postpartum, and the differential diagnosis of severe headaches in pregnancy should be broad, and include RCVS, PRES, cerebral venous sinus thrombosis (CVST), arterial dissection, pituitary apoplexy/Sheehan's syndrome, or subarachnoid hemorrhage (SAH). a. All pregnant patients with severe headaches should be screened for intensity at onset (i.e. thunderclap vs. gradual onset) and associated features (e.g. stiff neck, decreased level of consciousness, nausea/vomiting, visual loss or focal neurologic deficits); and if these are identified, the patient must be further investigated with maternal brain imaging, and potentially lumbar puncture if imaging is inconclusive. Refer to Diagnostic Imaging section below for more information. iv. In pregnant women who present to the hospital with acute stroke, gestational age should be established where possible. This will allow for the provision of appropriate risk/benefit information on available management strategies and information on the potential impacts to both mother and fetus.
v. A urine or serum beta-hCG blood test is a recommended laboratory investigation for women of reproductive age with acute stroke or TIA who could be pregnant. Refer to CSBPR PreHospital and Emergency Stroke Care section 4 for full list of suggested initial laboratory tests. a. Efforts should be made to first rapidly establish likelihood of pregnancy by patient history, known last menstrual period, and use of contraception. b. For acute stroke patients, drawing blood work and awaiting test results for pregnancy should not delay imaging or decisions regarding treatment with acute stroke treatments.
Refer to CSBPR Acute Stroke Management module, section 4 for initial assessment and management of acute stroke in the emergency department.
Refer to CSBPR Acute Stroke Management module, section 4 for additional information on initial imaging of a suspected stroke patient (www. strokebestpractices.ca).
i. Counseling of pregnant patients on imaging-associated risk for both mother and fetus may be considered and coordinated between clinical and imaging teams. Note: Many clinicians remain overly concerned about the fetal risk associated with neuroimaging and ionizing radiation (CT). The fetal dose of radiation, and corresponding risk, associated with neuroimaging is extremely small.
Intravenous thrombolysis and endovascular treatment
The use of alteplase has classically been considered a relative exclusion criterion during pregnancy, largely because of the absence of clinical trial data to support its safety for mother and fetus. Case reports and series on the pregnancy outcomes of women who received intravenous alteplase during all trimesters indicate that, generally, the mother experienced marked
ii. Where an acute stroke is suspected, given the severe maternal risk caused by potential delay in diagnosis when compared to the minimal risk to the fetus with CT imaging, it is acceptable to conduct a CT scan of the head without first establishing pregnancy. a. For severe disabling stroke, standard of care for the diagnosis of acute stroke includes immediate imaging of both the brain and cerebrovascular system, within minutes of hospital arrival. Note: in patients displaying mild or transient stroke symptoms who are not being considered for emergent stroke intervention, brain imaging and vessel imaging should still be undertaken in accordance with timelines as defined in CSBPR Acute Stroke Management section 2. b. In most centers, this is achieved with immediate CT with CT angiography (CTA) of the head and neck. In some cases, CT Perfusion (CTP) or MRI may also be used to identify potential candidates for intravenous thrombolysis with alteplase and/ or acute endovascular thrombectomy. Both CTA and CTP use intravenous contrast and have higher doses of radiation than a CT head. c. In the time-sensitive emergency of severe disabling stroke, the health of the mother is paramount and CT with contrast is often the most accessible option to determine if patients are eligible for acute endovascular thrombectomy.
Where immediately available as part of a local acute stroke protocol, MRI of the brain with time-of-flight (non-contrast) imaging of the blood vessels may be used in place of CT/CTA to visualize the brain and vasculature (Refer to iii below). In select cases (e.g. presence of a hyperdense middle cerebral artery on non-contrast CT), CTA may be deferred in a pregnant woman in favor of moving directly to digital subtraction angiography for potential treatment of a proximal occlusion appropriate to explain the symptoms. d. Based on currently available evidence, the ionizing radiation associated with non-contrast CT head in pregnant patients does not expose the fetus to the high levels of radiation associated with increased risks of abortion, malformation, or other adverse pregnancy outcomes. 19, 20 A typical CT of the mother's head carries a fetal radiation dose exposure of 0.001 mGy. The typical occupational limit for fetal radiation is 5 mGy. Therefore, the fetal exposure from a maternal CT head is 5000 times less than the allowable occupational exposure and carries negligible risks for fetal malformation, abortion, or other pregnancy complications when compared to the general risks of pregnancy. [22] [23] [24] A typical CT head exposes the fetus to a negligible amount of radiation. Owing to the distance of the mother's head away from the uterus, there is a low amount of scatter and minimal fetal exposure. If CT scanning is used, efforts to minimize radiation exposure such as shielding of the abdomen/pelvis and minimizing extra scans are encouraged. e. There is a lack of available evidence on any known harm identified in human or animal studies of exposure to CT contrast dye. For breastfeeding, less than 1% of CT contrast dye is excreted in breast milk; of that, less than 1% is absorbed in infant gastrointestinal tract. Continuation of breastfeeding after exposure to CT contrast dye is reasonable.
iii. MRI, without gadolinium, does not expose the mother or fetus to ionizing radiation. When appropriate and available, and where the results can assist in clinical decision-making, MRI is therefore a reasonable option in pregnancy. However, in many centers, MRI is not readily and rapidly available; in the setting of disabling acute stroke, the most available imaging modality should be utilized to avoid delaying treatment. a. Time of flight imaging modalities (non-contrast MR angiography or venography) can often provide sufficient vascular information for emergency stroke decision-making in pregnancy and is preferred over contrast scanning. b. MRI at 1.5 or 3.0 tesla (T) without gadolinium does not increase the risk of adverse fetal outcomes, whether exposure occurs in the first trimester 18 or later. 19 MRI of the fetus has been shown to be safe in the second and third trimesters. 25 c. Gadolinium exposure in the first trimester may be associated with an increased risk of adverse outcomes. 18 Even outside of pregnancy, gadolinium is rarely needed in the setting of acute stroke diagnosis. Therefore, gadolinium is not recommended for stroke assessment in women with known pregnancy.
iv. Institutional protocols on imaging in pregnancy and established methods for counseling pregnant women, or their next-of-kin, on risk/benefits and decision-making may be helpful to assist practitioners, especially in the time-sensitive setting of hyperacute stroke. a. When possible, pregnant women should be wedged during supine imaging to allow for left uterine displacement, as of 24 weeks or when symptoms (e.g. lightheadedness) necessitate.
improvement following treatment and delivered a healthy baby, while the incidence of symptomatic intracerebral hemorrhage (sICH) was low, and comparable to non-pregnant patients. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Treatment with thrombolytic agents in the early postpartum period (48 h) is more controversial, given the increased risk of bleeding. Akazawa and Nishida 37 documented 13 cases where thrombolytics were given to women during this period. The most common indication for treatment in this series was pulmonary embolus, with a single case of ischemic stroke. Blood transfusions were required in all but one case.
To date, there are four reported cases of women treated with mechanical thrombectomy during pregnancy, all of which occurred during the third trimester. 38, 39 Second-generation devices were used in all cases. The maternal outcomes were good in three cases (mRS scores 0-1), with greater residual disability in the fourth case (mRS 2). The pregnancy was ongoing in one published report, 38 while three women delivered healthy babies. There were no cases of sICH.
Acute ischemic stroke treatment: intravenous thrombolysis and endovascular treatment
Refer to CSBPR 2018 Acute Stroke Management module, section 5 for administration of hyperacute stroke treatments for ischemic stroke. All consensus statements in this section are aligned to these recommendations.
Intravenous alteplase
i. Acute stroke treatment decisions should be based on severity of symptoms, medical condition of the patient, and, when available, consideration of the personal values and wishes of the patient and her family or next-of-kin.
ii. Treatment options for a pregnant woman with an acute stroke should promptly be considered in consultation with an interdisciplinary team with expertise in neurology, obstetrics and gynecology, maternal-fetal medicine, and interventional radiology, where possible and available.
iii. Acute intravenous thrombolysis with alteplase has been shown to reduce morbidity in the non-pregnant population. There are a limited number of case reports published using alteplase during pregnancy. 36, 40 iv. It is reasonable to consider giving IV alteplase to a pregnant patient with disabling ischemic stroke who meets existing criteria for thrombolysis. The risk-benefit considerations can be complex in the setting of pregnancy; thus, the decision should be undertaken in consultation with a physician with experience in acute stroke treatment either in person or through telestroke modalities.
41,42
Refer to CSBPR Acute Stroke Management module, section 5 for administration of acute stroke treatments for ischemic stroke. a. While there are risks of hemorrhage (intracranial and otherwise) from intravenous alteplase, the decision to administer acute thrombolysis should be based on the maternal risks associated with the acute stroke. b. Placental abruption can occur with or without alteplase, and it is not known whether alteplase increases the risk of abruption. Close monitoring and prompt recognition is important. c. Alteplase is a large molecule (59,000 daltons) and does not cross the placenta. 43 Therefore, alteplase is not expected or known to pose direct intracranial or systemic bleeding risks to the fetus. d. The safety and efficacy of intravenous alteplase in the early postpartum period (<14 days after delivery), especially related to risk of maternal postpartum hemorrhage, have not been well established. Case reports suggest that bleeding risk may be increased after alteplase administration and may be further increased if given following Cesarean delivery. Maternal risk of postpartum hemorrhage should be balanced with the risk of a thromboembolic event. 37 The literature to guide assessment of risks from epidural or spinal anesthesia after alteplase administration is limited, but risks of bleeding complications may be increased.
Note: Intravenous alteplase is listed with the Food and Drug Administration (FDA) as pregnancy category ''C'' according to the package label, indicating ''possible risk'' only. There are limited case reports (approximately 30 at time of publication) of IV alteplase in pregnancy for stroke and other conditions, but only one case of fetal demise due to abruption. Other, more common causes of fetal demise in these case reports are related to spontaneous or planned abortion which may also be related to the underlying illness.
Endovascular thrombectomy
i. Pregnancy should not be considered a contraindication to angiography and endovascular thrombectomy (EVT) for proximal large vessel occlusions causing acute disabling stroke. These cases should be treated according to existing guidelines (refer to 2018 CSBPR Acute Stroke Management module, section 5 on endovascular thrombectomy).
Acute hemorrhagic stroke treatment
Pregnancy and the postpartum period are associated with an increased risk of cerebral hemorrhage. Although estimates vary, and reports are limited, the incidence of intracerebral hemorrhage (ICH) per 100,000 pregnancies have been reported to range between 4.6 44 and 25.4, 45 and a recent meta-analysis found rates of 12/100,000. 1 Relative to women who have had strokes outside of pregnancy, the risk of ICH appears to be highest in the six weeks after delivery (RR¼28.3, 95% CI: 13.0-61.4). The risk of ICH during pregnancy, relative to non-pregnancy, is slightly elevated as well (RR¼2.5, 95% CI: 1.0-6.4) 46 The most common risk factors for ICH during pregnancy include increased age, cardiac disease, hypertension, eclampsia/ preeclampsia, and smoking. 47 The most common etiologies for ICH include vascular anomalies and arteriovenous malformations (AVMs). 45 While in-hospital mortality for pregnancy-associated ICH has been reported to be as high as 20.3%, 47 a more recent report suggests that compared to non-pregnant women, pregnant women had significantly lower in-hospital mortality (10.1% vs. 19.6%, p¼0.002) and were more likely to be discharged home (56.2% vs. 47.2%, p¼0.02). 6 There are several factors that may increase the risk of AVM or aneurysmal rupture during pregnancy, including increased blood volume and cardiac output, and structural changes in the vascular wall. However, whether pregnancy truly increases the risk of rupture is a topic of ongoing debate. Liu et al. 48 reported the odds for rupture of AVM during pregnancy and puerperium were significantly lower compared with the control period (OR¼0.71, 95% CI: 0.61-0.82). Similarly, Bateman et al. 47 reported no significant increased risk of intracranial hemorrhage from cerebrovascular malformations during pregnancy (0.50 vs.0.33 per 100, 000 person-years for pregnant vs. non-pregnant patients, respectively). In contrast, Porras et al. 49 reported a significant increase in the risk of AVM hemorrhage during pregnancy or the puerperium among 191 women with AVM who became pregnant before obliteration. The annual rate of hemorrhage was 5.7% in pregnant women compared with 1.3% in non-pregnant women (RR¼4.43, 95% CI: 1.98-8.65, p<0.001).
Management of acute hemorrhagic stroke during pregnancy (SAH, ICH)
i. Following imaging confirmation of a hemorrhagic stroke, vessel imaging (time of flight MR Angiography, CTA, catheter angiography) is preferred to guide further management decisions except in presence of devastating hemorrhage with very poor prognosis. The overall goal is to minimize the risk of rebleeding.
ii. Pregnancy should not be regarded as a contraindication for angiography and endovascular treatment of a vascular cause for hemorrhage. a. Endovascular procedures are reasonable to consider, where appropriate and expertise is available without delay. b. Efforts to avoid or reduce the risk of fetal injury are reasonable, such as abdominal shielding and judicious exposures. c. It is not reasonable to delay or defer necessary maternal care secondary to the pregnancy. The acknowledgment of possible fetal risks is appropriate: risks may include radiation and contrast exposure, infections, and arterial puncture complications that could result in both maternal and fetal complications.
iii. For ICH, priority should focus on managing blood pressure and on identifying and correcting coagulopathies. Efforts should be undertaken to reduce blood pressure to an initial target of below 160/110 mmHg, followed by titration of medications to consistently lower than 140/90 mmHg. Refer to SOGC Hypertensive Disorders of Pregnancy guidelines for additional management information. Refer to Hypertension Canada Guidelines for Management of Hypertension in Pregnancy 2018 for medication selection and dosing.
a. Efforts to avoid or reduce the risk of fetal injury such as abdominal shielding and judicious use of x-ray exposures are reasonable. b. It is not reasonable to delay or defer necessary maternal care for severe disabling stroke secondary to the pregnancy. The acknowledgment of possible fetal risks is appropriate: risks may include radiation and contrast exposure, infections, and arterial puncture complications that could result in both maternal and fetal compromise. However, given the very high morbidity and mortality associated with acute ischemic stroke due to large vessel occlusions, these risks are generally outweighed by the benefits of treatment.
ii. For patients with large vessel occlusions eligible for and with rapid access to endovascular thrombectomy, proceeding directly to endovascular thrombectomy without administering intravenous alteplase could be considered.
Anesthetic management for acute stroke treatment during pregnancy
Women who are pregnant and experience a stroke may require anesthesia associated with procedures related to delivery, the need for emergency neurosurgery, or both. Whether Cesarean section or neurosurgical intervention should be prioritized or performed simultaneously is an important issue, as is the decision to use general or regional anesthesia when a Cesarean section is indicated. In addition to significant maternal physiological changes, the potential for fetal harm should be considered during anesthetic management. The goals of anesthesia should include both fetal and maternal well-being.
a. In pregnancy, first-line medications for blood pressure control are labetalol, methyldopa, and long acting nifedipine. Selection of specific antihypertensive medication should consider side-effect profiles for the woman, fetus, or neonate.
Refer to Hypertension Canada Guidelines for Management of Hypertension in Pregnancy 2018 for medication selection and dosing. b. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers-two common classes of medications used in stroke prevention-carry an increased risk of fetal complications (kidney injury) and low amniotic fluid, especially if used after the first trimester. These medications should be discontinued prior to pregnancy or as soon as a pregnancy is recognized. If they have been inadvertently taken, prompt referral to a regional center for detailed fetal structural ultrasound and counseling is encouraged.
iv. For cases of unruptured cerebral aneurysm, an MRI without contrast (with time-of-flight MR angiography) is reasonable to define the lesion. a. If the patient's neurological and overall clinical status is stable, consider deferring treatment until the postpartum period.
v. Ruptured aneurysm should be treated urgently based on accepted standards of care. a. The choice to coil or clip the ruptured aneurysm should be based on the best available option for the patient, regardless of her pregnancy status. b. Efforts to reduce hypertension to a target of less than 140/90 mmHg, if clinically indicated, are reasonable. c. The treatment of ruptured aneurysms requires an urgent interdisciplinary approach including neurosurgeon and/or endovascular interventionalist, neurologist, and physicians with expertise in maternal-fetal medicine whenever possible. d. Maternal safety and outcomes should be considered throughout all discussions of management and may require treatment decisions that potentially compromise the pregnancy or the fetus. e. If the timing corresponds with a viable gestational age, where neonatal outcomes are considered favorable, an interdisciplinary team including, for example, neurosurgery and/or neurointerventionalists, maternal-fetal medicine, obstetrics, neonatology, neurology, anesthesia, and obstetrical medicine where available may consider the benefits of a concurrent Cesarean delivery. f. If the timing corresponds to a previable gestational age, treatment should proceed as it would outside of the context of pregnancy in order to maximize maternal safety and outcomes.
vi. Arterio-venous malformation (AVM) should be treated based on accepted standards of care. a. Management of unruptured AVM (without bleeding) requires an individualized approach. Considerations for medical management (i.e. blood pressure control to primary prevention targets and treatment of emerging neurological symptoms), with or without surgical intervention, should be guided based on patient factors and the features of the AVM. b. The choice of treatment for ruptured AVM should be based on the best available treatment option(s) for the patient, regardless of her pregnancy status. c. Low-grade symptomatic AVM amenable to surgical resection should be resected (with or without pre-operative embolization) in the same time-frame as it would be for non-pregnant women, with every possible effort to reduce fetal risk of injury during endovascular or surgical treatment. d. The treatment timing of high-grade AVM, requiring multimodality approach (endovascular/surgery or endovascular/radiosurgery), should be made with an interdisciplinary team, including neurosurgery, neurology, and expertise in maternal-fetal medicine. e. Maternal safety and outcomes should be considered throughout all discussions of management and may require treatment decisions that potentially compromise the pregnancy or the fetus. 1. If the timing corresponds with viable gestational age, where neonatal outcomes are considered favorable, an interdisciplinary team including, for example, neurosurgery and/or neurointerventionalists, maternal-fetal medicine, obstetrics, neonatology, neurology, anesthesia, and obstetrical medicine where available may consider the benefits of a concurrent Cesarean delivery. 2. If the timing corresponds to a previable gestational age, treatment should proceed as it would outside of the context of pregnancy in order to maximize maternal safety and outcomes. 3. The acknowledgment of possible fetal risks is appropriate: risks include radiation and contrast exposure, as well as blood loss that could result in both maternal and fetal compromise.
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Once the etiology of the stroke is determined, secondary prevention strategies can be initiated, as appropriate. The use of antithrombotics and/or antihypertensives and other treatments may be required to reduce the risk of future events.
The same approaches to rehabilitation in the nonpregnant condition can be applied to a woman who is pregnant, with modifications as needed. The elements associated with improved functional outcome following a moderately disabling stroke include adequate intensity of therapy, task-oriented training, and excellent team coordination. Early, intensive rehabilitation has been shown to improve functional recovery. It is important that the rehabilitation therapies be tailored to the tasks that need to be retrained and developed, as well as to the activities of the patient's choice and to their social roles. The need for a highly coordinated, specialized team, who meet regularly to discuss the rehabilitation goals and progress, is also vital.
5.0 Anesthetic management in the setting of acute stroke during pregnancy i. The anesthetic care can be tailored to the needs of the pregnant woman and her fetus for the specific clinical scenario, which may include, but is not limited to, concurrent Cesarean delivery and resection of a vascular lesion, or the peripartum management of a woman with an intrapartum stroke.
ii. Optimal care can be facilitated by: a. Close communication between the anesthesia, neurology, maternal-fetal medicine, and obstetrics teams including discussion of optimal blood pressure parameters and intracranial pressure related to stroke management. b. Consideration of potential anesthesia-related benefits (e.g. neuraxial anesthesia for labor to allow for an assisted delivery, thereby reducing Valsalva efforts, and decreasing circulating catecholamines). c. Identification of stroke-or treatment-related contraindications to neuraxial anesthesia (e.g. the presence of mass effect and/or increased intracranial pressure or active anticoagulation). 50 d. Interdisciplinary team goals for maternal blood pressure and intracranial pressure that can be incorporated into overall anesthetic plans. e. In the setting of stroke, alternatives to general anesthesia should be considered to avoid sedation if possible. f. Where general anesthetic cannot be avoided, hemodynamic changes inherent to intubation and extubation should be taken into consideration.
Early poststroke management in a pregnant woman
i. The risk of stroke is highest in the postpartum period (usually considered the first 12 weeks following delivery). Women at risk should be alerted to signs of stroke occurrence or recurrence and the need to immediately contact emergency health services or notify healthcare professionals if already in hospital. a. Women who are postpartum and with previous history of stroke require education and monitoring, especially in the first six weeks after delivery when recurrent stroke risk rates have been reported to be highest.
ii. Etiology of stroke should be established to guide early recurrent/secondary stroke prevention management decisions.
iii. Rehabilitation should start early during acute care following current standards of rehabilitation for stroke patients. 51 Rehabilitation goals and plans may need to be modified based on patient factors and in consultation with obstetrics, neurology and physical medicine and rehabilitation.
iv. Secondary prevention decisions including antithrombotic use, blood pressure management, and other risk reduction can be complex in pregnancy. Refer to Secondary Prevention of Stroke during Pregnancy module for detailed information on stroke prevention management and pharmacotherapy.
Poststroke antenatal obstetric considerations for women with a stroke in pregnancy
Pregnant women with a history of stroke, or with neurological symptoms consistent with stroke, should be managed and plan to deliver at a facility equipped to treat patients with stroke, where full-time neurosurgeons and/ or diagnostic imaging tools suitable for the diagnosis of stroke are readily accessible. 52 A nationwide survey of 1582 facilities across Japan noted that one of the top three factors associated with maternal mortality (due to a stroke event) was an onset-to-diagnosis time of greater than 3 h. 52 Where neurological interventions are required, Cesarean delivery should be performed before craniotomy after 28 to 32 weeks of gestation as interventions during neurosurgery (e.g. management of hypotension, use of osmotic diuretics, and mechanical hyperventilation) may pose a risk to the fetus. 53 
Intrapartum consideration
The care women receive during labor not only affects her well-being, but the well-being of her child as well.
Among healthy women, type of delivery and use of anesthetic are all areas of considerations. When managing the risk of stroke, the above intrapartum considerations must be carefully reviewed for the health of both the mother and baby. While a women's risk of stroke increases during pregnancy, her odds of a cerebrovascular event following a Caesarean delivery is significantly greater compared to a vaginal delivery. 54 In fact, Caesarean delivery is noted to be a significant predictor of stroke (adjusted OR¼3.56, 95% CI: 2.62-4.83) in both the peripartum and postpartum period compared to vaginal births.
Postpartum management
The postpartum period is associated with an increased risk of both stroke and cerebral hemorrhage. 40 While the median time of stroke onset has been observed to be 8 days postpartum (range 3 to 35 days), 55 the risk is greatest within the first six weeks after delivery (OR: 10.8, 95% CI: 7.8-15.1) 56 and remains significant up to 12-months after delivery among women with preeclampsia-eclampsia (hemorrhagic stroke OR: 19.9, 95% CI: 7.75-51.11). 57 Women with pregnancy-related 7.0 Poststroke antenatal obstetric considerations for women with a stroke in pregnancy i. Where possible, obstetric care should be managed with access to, or in collaboration with, stroke care. Risk of recurrence and practicality of care should be considered when decision regarding place of care is made.
ii. Antenatal fetal surveillance regimens should follow local protocols established for all pregnant women. Increased fetal surveillance in pregnancy may be required in women with a history of stroke given the likelihood of underlying vascular disease and other comorbidities that may increase the risk of growth restriction or compromised fetal well-being. a. Placental studies in the second trimester and serial growth ultrasound studies in the third trimester should be considered.
iii. Timing of delivery decisions should take into consideration the general condition of the mother, gestational age, fetal status, and neonatal viability.
iv. Antenatal anesthesia consultation, and the creation of an anesthetic plan of care, is warranted to avoid any uncertainty regarding neuraxial anesthesia in labor.
v. Wherever possible, decisions should be made with an interdisciplinary team (e.g. maternal-fetal medicine, obstetrics, neonatology, and neurology) and should consider the preferences of the patient and family.
vi. Postpartum depression and depression after a stroke both have high incidence. Consider screening pregnant patients who experience a stroke for signs and symptoms of depression, especially those patients with previous history of mood disorders. a. As with all pregnancies, screening for depression in the postpartum period should be considered for all patients who have experienced a stroke in pregnancy. b. Pathways for referral to appropriate care providers for management of depression may be established.
Refer to Secondary Prevention of Stroke during Pregnancy module for detailed information on stroke prevention management and pharmacotherapy.
International Journal of Stroke, 13 (7) stroke are less likely to have vascular risk factors such as hyperlipidemia or history of thromboembolism and more likely to have cerebral venous thromboses. 58 Although rare, postpartum stroke carries a mortality rate of 2%-10%. [59] [60] [61] Accordingly, secondary stroke prevention, including blood pressure-and diabetes management, should be incorporated into the postpartum period to monitor for thrombotic complications. For high-risk women, extending the recommended duration of prophylactic anticoagulant therapy may be worth examining. As well, all women should be educated about the signs of both preeclampsia and potential postpartum stroke, such as difficulty breathing, sudden and severe headaches, or sudden change in consciousness, speech, strength, vision, balance or sensation to one side of the body. 56 
Summary
The 2018 Canadian Stroke Best Practice Consensus Statement on acute stroke management during pregnancy provides clinicians with guiding principles to manage women who experience a stroke during pregnancy. The consensus statement emphasizes the need for coordinated shared care with an interdisciplinary team involving both stroke experts and obstetric specialists along with the patient and their family. System leaders for both stroke and maternal-fetal medicine ii. In situations where some amount of increased intracranial pressure can be tolerated (i.e. low risks of Valsalva), vaginal births without assisted delivery may be considered.
iii. Women in whom increased intracranial pressure should be avoided may be candidates for a vaginal birth with an assisted second stage of labor. a. Expert opinion suggests that an assisted second stage of labor, with vacuum or forceps, may reduce Valsalva efforts in women where increased effort or intracranial pressure may be contraindicated. b. Neuraxial anesthesia can facilitate a forceps or vacuum-assisted 2nd stage vaginal delivery to avoid Valsalva in the absence of contraindications such as increased intracranial pressure/mass effect. Typically, a concentrated dose of local anesthetic is administered through the epidural catheter at the end of the first stage of labor to diminish the sensation of needing to push and any pain associated with the subsequent forceps or vacuum procedure.
iv. In women at very high risk of intracranial bleeding (acute ischemic stroke with hemorrhagic transformation, an unsecured aneurysm, AVM, or a CVST with elevated intracranial pressure), Cesarean delivery may be considered, acknowledging that there are inherent maternal risks with Cesarean delivery as well.
v. Decisions regarding mode of delivery should also take into consideration patient preferences and should be made on an individualized basis.
Intrapartum fetal Surveillance
i. Intrapartum fetal surveillance should follow local protocols and guidelines and be based on gestational age and the preferences for fetal intervention by the patient.
ii. A history of stroke, and any corresponding vascular abnormalities, places the woman in a risk category that would render continuous fetal monitoring appropriate.
iii. In cases where delivery is anticipated in preterm or extremely preterm gestations, potentially due to stroke-related complications, maternal-fetal medicine and neonatal counseling is necessary to guide plans for intervention and to implement a plan for fetal monitoring and neonatal management, where appropriate.
should consider the broader needs of a woman who experiences a stroke during pregnancy and develop systems that enable efficient access to the appropriate specialists as outlined in this consensus statement. The evidence base for this consensus statement varies in its scope and strength, reflecting the practical challenges in conducting randomized controlled trials with this specific sub-population. The evidence for acute stroke care has advanced significantly in the past five years with the emergence of endovascular thrombectomy as an established evidence-based treatment for acute stroke. This is positive news for women who experience a stroke in pregnancy as this may be an alternative to intravenous thrombolysis for large vessel occlusions and potentially pose less risk to the fetus. We have drawn upon stronger evidence from both maternal-fetal medicine and stroke literatures to develop these statements. We urge clinicians to collect and share data on management of women with stroke prior to or during pregnancy, documenting and reporting care and outcomes for large cohorts to help build a stronger knowledge base. This consensus statement continues to be a work in progress and will be regularly updated every three to five years to integrate newly released data to help ensure optimal patient care and outcomes.
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